NCT04163263View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 4, 2019

Primary Completion Date

November 11, 2020

Study Completion Date

November 11, 2020

Conditions
Moderate to Severe Acne Vulgaris
Interventions
DRUG

BOS-356

topical gel

DRUG

Vehicle

topical gel

Trial Locations (7)

27262

Dermatology Consulting Services, High Point

32771

International Clinical Research, Sanford

77845

J&S Studies, Inc., College Station

78213

Progressive Clinical Research, San Antonio

78759

DermResearch, Inc., Austin

94538

Center for Dermatology Clinical Research, Fremont

Unknown

Innovaderm Research, Inc., Montreal

Sponsors
All Listed Sponsors
lead

Boston Pharmaceuticals

INDUSTRY

NCT04163263 - Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris | Biotech Hunter | Biotech Hunter